| The Development and Application of a Monoclonal Antibody Purification Platform
|
|
| By
Judy Glynn
,
Timothy Hagerty
,
Timothy Pabst, PhD
,
Gopinath Annathur
,
Kristin Thomas
,
Paul Johnson
,
Natarajan Ramasubramanyan, PhD
,
Paul Mensah, PhD
|
|
| A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
|
|
| Economic Drivers and Trade-Offs in Antibody Purification Processes
|
|
| By
Suzanne S. Farid, PhD
|
|
| The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
|
|
| A Purification Platform for the Production of MAbs from Fermenters with Titers of 5 g/L and Beyond
|
|
| By
Jim Davies
|
|
| New techniques can greatly improve the MAb purification process.
|
|
| Platform Technology for Developing Purification Processes
|
|
| By
Michel H.M. Eppink
,
Rick Schreurs
,
Anke Gijsen
,
Kees Verhoeven
|
|
| The future of therapeutic MAbs lies in the development of economically feasible downstream processes.
|
|
| Purification Strategies to Process 5 g/L Titers of Monoclonal Antibodies
|
|
| By
Melody Trexler-Schmidt
,
Stefanie Sze-Khoo
,
Amber R. Cothran
,
Binh Q. Thai
,
Sandy Sargis
,
Benedicte Lebreton
,
Brian Kelley
,
Gregory S. Blank
|
|
| Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
|
|
| Advances in Non-Protein A Purification Processes for Human Monoclonal Antibodies
|
|
| By
Alahari Arunakumari, PhD
,
Jue (Michelle) Wang, PhD
,
Gisela Ferreira, PhD
|
|
| In three non-affinity purification processes based on cation exchange capture with high binding capacity, applying a host cell protein exclusion strategy enabled robust scale up and better economics.
|
|
